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Abstract: The objective of investigating some biochemical parameters like urea, creatinine, Hb and other 
parameters as CRP and leptin in the serum of ESRD patients on hemodialysis pre-dialysis.  
Method: Sample of 250 cases which consists of the patient with ESRD, their mean ages were 52.66 ± 12.55 years 
with ranged from 18-83. Moreover, under hemodialysis treatment not less than three months. Apparently, 20 healthy 
subjects were selected as (control) for comparison.  
Results: The results showed that there was a significant increase (p<0.01) in the serum urea, creatinine, CRP, and 
leptin. While, revealed significant (p< 0.05) decrease in the levels of uric acid, serum glucose, albumin, inorganic 
phosphorus, potassium, Hb and platelet in patients before dialysis compared to the control group. Non-significant 
(p>0.05) is in total cholesterol, calcium and total protein in patients undergoing hemodialysis which was compared 
to the control group. It is concluded from the findings of the present study, it shows a highly significant increased 
serum concentration of leptin as well as, elevated serum values of CRP. Whereas a highly significant decrease in 
GFR and CrCl result from loss of the ability of the kidney to clearance. Also, abnormal mineral parameters and 
hematological parameters. According to the results of this study, serum total protein and cholesterol cannot be used, 
as a diagnostic marker of nutrition disorders in patients on regular hemodialysis requires further investigation and 
clarification. 
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1. Introduction 
 
The condition when the kidneys lose their normal 
functionality called renal failure [1]. It occurs when the 
kidneys cannot properly remove wastes that cause a 
buildup of waste and fluid in the body [2]. Renal 
impairment continues to be associated with high 
morbidity and mortality [3]. In the other way, renal 
failure is characterized by a wide change of 
biochemical instabilities and many clinical symptoms 
and signs [4]. Leptin plays a vital role in promoting 
anorexia and malnutrition in uremic patients [5]. 
Factors like the decline in renal clearance and 
erythropoietin level and inflammation have been 
supposed to raise leptin level in end-stage renal disease 
(ESRD) patients [6]. The previous study revealed high 
serum levels of C-reactive protein (CRP) and cytokines 
elevate leptin gene expression [7,8]. The result of renal 
failure is usually death unless the blood is filtered by 
some other means [9]. Dialysis keeps the body in 
balance [10]. It is a procedure that removes excess 
fluids and toxic end products of metabolism such as 
urea from the plasma, when the kidneys fail and correct 
electrolytes balance by dialyzing the patient’s blood 
against fluid containing no urea but with appropriate 
concentrations of electrolytes, free-ionized calcium and 
some other plasma constituents [11]. Hemodialysis 
(HD) is a medical method that uses a special machine to 
filter waste products from the blood and to restore 
normal constituents to it when the kidneys are unable to 
do so [12]. Hemodialysis is frequently done to treat 
patients with (ESRD). Under such circumstances, 
kidney dialysis is typically administered using a fixed 
schedule usually over four-hour of three times per week 
[13]. The primary goal of hemodialysis is to restore the 
intracellular and extracellular fluid environment that is 
characteristic of normal kidney function [14]. This is 
accomplished by the transport of solutes such as blood 
urea and bicarbonate take place down a concentration 
gradient from the circulation into the dialysate and in 
the reverse direction [15]. 
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2. Material and Methods 
 
The condition when the kidneys lose their normal 
functionality called renal failure. During the time from 
April 2016 to March 2017, a cross-sectional study was 
conducted with 250 HD patients (138 males and 112 
females). The patients were collected from four 
different major HD centers in public hospitals in 
Baghdad capital, their mean age was 52.66 ± 12.55 
years with ranged from 18-83. Apparently, 20 healthy 
subjects were selected to participate as a normal group 
(control) for comparison. They were collected from 
medical staff and relatives who were free from signs 
and symptoms of renal disease. A blood sample was 
taken from the patients pre-dialysis and healthy subjects 
to perform the study which included measurement pre-
dialysis of the following variable, renal function tests: 
urea, creatinine, uric acid, glomerular filtration rate 
(GFR), and creatinine clearance (CrCl). To calculate 
each one of the (Serum Urea, Creatinine, and Uric 
acid), used Randox Kit specific for each parameter by 
Roche Cobas c 111 clinical chemistry analyzer, for 
assay the glomerular filtration rate (GFR) at baseline 
and during follow-up was estimated by the following 
formula: eGFR-EPIcreat = 141 × min (SCr/݇, 1) ߙ × 
max (SCr/݇, 1) − 1209 × 0.993 Age [×1.018 female] 
[×1.159 if black], Where SCr is serum creatinine in 
mg/dL, ݇ is 0.7 for females and 0.9 for males, ߙ is 
−0329 for females and −0411 for males, min is the 
minimum of SCr/݇ or 1, and max is the maximum of 
SCr/݇ or 1 (Levey et al., 2009) [16]. Whereas CrCl 
estimated by Cockcroft-Gault equation (C-G = [140 – 
age (years)] × weight (kg) × 1.23 [if male] / sCr 
(μmol/L) (Pierrat et al., 2003) [17]. Biochemical 
parameters like albumin, total protein, cholesterol and 
blood glucose. In addition, electrolytes levels:  calcium, 
phosphorus, potassium, sodium, and chloride, were 
determined by a Randox kit for each parameter and RX 
Monza semi-automated clinical chemistry analyzer for 
analysis. Whereas leptin level and C-reactive protein in 
serum that they were estimated by Enzyme-Linked 
ImmunoSorbent Assay (ELISA) method. In the current 
study, hematological disorder Hb, PCV, lymphocyte, 
RBC, and platelets were measured by RUBY 
Hematology Analyzer. All the results are presented as 
mean ± SE. The Statistical Analysis System- SAS 
(2012) program was used to effect of different factors 
in study parameters. The least significant difference –
LSD test was used to significant compare between 
means in this study. 
 
3. Results and Discussion 
 
3.1 Evaluate the changes in renal function tests 
In the Table (1) from current study, the urea and 
creatinine high significant (P<0.01) increased in 
patients when compared with control group, this is due 
to a decline in the number of nephrons [18]. This 
increase in urea and creatinine level occurs because in 
CRF the kidney loses its ability to eliminate 
nitrogenous wastes from the blood results in 
accumulation of these substances in the blood [19]. 
This result agrees with [20,21,22,23], they showed a 
highly significant increase in urea and creatinine 
concentrations in chronic kidney disease. Uric acid 
levels were normal range in both groups with a 
significant (p<0.05) increase in patients group, this 
result of the present study agreed with those obtained 
by [20,24]. Elevated serum uric acid levels as observed 
in current study may result secondary to decreased 
glomerular filtration, decreased tubular secretion or 
enhanced tubular reabsorption. Decreased urate 
filtration can contribute to the increase in a uric acid of 
renal insufficiency [25], which in turn the fall in the 
glomerular filtration rate (GFR) in CRF patients [26]. 
The value of urea as a test of the renal function depends 
on the observation that serum/plasma urea 
concentration reflects GFR: our study demonstrated that 
the GFR level significant (p<0.01) decrease in the 
patients when compared with control subject and this 
result agree with [27,28]. However, as the GFR falls, 
the creatinine clearance increases because of an 
increased tubular secretion of creatinine [29], as GFR 
declines, plasma/serum urea rises [30]. To determine 
the GFR for clarifying the stage of renal disease uses 
the level of creatinine in the blood. These results are 
supported by findings of other workers Abdul Wahid et 
al., who reported that as a result, this leads to loss of the 
ability of the kidney to clearance which can explain the 
decline of creatinine clearance level [31]. 
 
Table 1. Renal function tests in HD patients and healthy individuals. 
 
Parameters 
Groups 
P-value 
Control Patients 
Urea mg/dl 18.60 ± 0.80 129.27 ± 12.78 0.0001 ** 
Cr mg/dl 0.620 ± 0.02 6.96 ± 0.76 0.0001 ** 
Uric Acid mg/dl 5.42 ± 0.20 7.00 ± 0.63 0.0448 * 
GFR mL/min per 1.73 m2 122.40 ± 1.88 8.69 ± 1.02 0.0001 ** 
CrCl mL/minute 109.20 ± 4.23 13.74 ± 0.96 0.0001 ** 
 Mean ± SE 
 NS: Non-Significant. 
 ** Significant difference at (p< 0.01). 
 Significant difference at (p< 0.05). 
 
3.2 Evaluate the changes in some biochemical 
parameters tests 
In the present study, we showed, in the Table (2). 
There was non-significant difference (P>0.05) between 
patient and control in level of serum total protein, these 
results were accordance to that found by [32,20]. The 
results of normal total protein concentration were not 
inconsistency to those results obtained by other studies 
[33,34], they found that there was a non-significant 
difference when protein and albumin were reduced in 
their levels in the serum of patients with renal failure. 
Otherwise, serum albumin concentration is significantly 
lower (p<0.05) in renal failure patients when compared 
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with those of the control group. A reduction in the rate 
of albumin synthesis which may be caused by 
metabolic acidosis, impaired protein intake, and 
inflammation show a significant decrease in albumin 
level in HD patients [35,36]. Changes in the structure of 
basement membrane of glomeruli which consequent 
lead to the leakage of albumin and some low molecular 
weight proteins [37]. Proteinuria is considered as a 
marker of renal disease progression [38]. Restriction of 
protein intake [39] and protein malnutrition may 
attribute to such decrease in albumin and total protein 
of the serum of the corresponding patients [40]. This 
result is similar to the previous studies done by 
[31,41,23], they suggested that proinflammatory 
cytokines (TNF-a and interleukins) induce an acute 
phase response decreases hepatic synthesis of albumin 
and increases its catabolism the degradation of albumin. 
Thus, much of the observed association of albumin 
level with outcomes may be attributed to inflammation 
rather than malnutrition in the ESRD population [42].  
 
Table 2. Biochemical parameters tests in HD patients and healthy 
individuals. 
 
Parameters 
Groups 
P-value 
Control Patients 
Total Protein g/dl 6.18 ± 0.05 6.50 ± 0.17 0.1983 NS 
Albumin g/dl 5.36 ± 0.04 3.61 ± 0.04 0.0412 * 
Cholesterol mg/dl 171.20 ± 5.22 170.89 ± 9.51 0.675 NS 
FBS mg/dl 104.20 ± 7.66 122.19 ± 11.47 0.0382 * 
 Mean ± SE 
 NS: Non-Significant. 
 ** Significant difference at (p< 0.01). 
 Significant difference at (p< 0.05). 
 
In addition, The result demonstrated non-
significant (P>0.05) difference in serum cholesterol in 
chronic renal failure patients when compared with those 
of the control group, and this result is consent with 
[43,21,23]. Also, with study by Vazir, who stated that 
plasma Cholesterol concentration is normal or even 
reduced in ESRD [44]. Whereas these results were not 
like that found [45]. It is thought that malnutrition is a 
factor contributing to both the low lipid values and the 
high mortality in the dialysis patients [46]. On the other 
hand, the result demonstrated a significant (P<0.05) 
increase in serum glucose, elevated in FBS due to most 
of the patients have diabetes which causes damage to 
the kidneys, and this condition can lead to kidney 
failure [47]. The similar result has been reported by 
[48,43,49]. Several factors, including uremic toxins, 
may increase insulin resistance in ESRD, leading to a 
blunted ability to suppress hepatic gluconeogenesis and 
regulate peripheral glucose utilization [50]. 
 
3.3 Evaluate the changes in some Minerals levels 
tests 
From Table (3) in the present analysis a non-
significant decrease in calcium (Ca) (P>0.05) in ESRD 
patients as compared with their control groups. 
Decreased Ca level found when the kidneys fail, 
decreasing its ability to reabsorb calcium and leading to 
loss of calcium in the urine [47,51] and Patients with 
chronic renal failure tend to ingest less calcium in their 
diets than normal subjects. This result is compatible 
with [52,23]. In the current study, the patient takes 
exogenous sources of excess Ca include dietary Ca, 
Calcium supplements, Calcium-containing phosphate 
binders, and dialysate solutions that may be avoided the 
decline of calcium level. On the other hand, the table 
(3) shown a significant (p<0.05) increase in electrolytes 
levels phosphorus (PO4) and potassium (K) in patients 
when compared with control. Among mineral 
abnormalities, the most prevalent is 
hyperphosphatemia, which is a common problem 
among patients with ESRD [53,54]. Several studies 
have found a significant increase in serum phosphorus 
levels in patients in CKD [55,56,48]. These findings are 
similar to our study. We observed a statistically 
significant increase in serum PO4 levels in cases as 
compared to controls. The previous study reported a 
significant increase in PO4 levels and concluded that 
high levels of PO4 as a significant risk factor for 
mortality in CKD [57]. Raised serum (PO4) can result 
in renal mineralization, secondary hyperparathyroidism 
and potentially (not conclusive), to the progression of 
renal damage [58]. Medications and special diets can be 
used to help keep (PO4) levels down [59]. Potassium 
homeostasis is largely regulated by the kidney 
accounting for excretion of 90% of daily K loss [60]. 
Patients with renal failure, acute or chronic, have 
impaired regulatory mechanisms and are prone to 
hyperkalemia [61]. The results revealed a significant 
(p<0.05)  increase in the levels of K in patients with 
CRF when compared with control, thought to result 
from the failure to follow dietary K restrictions and 
ingestion of medications that contain K, or from an 
endogenous release of K, as in case of trauma or 
infection [19]. In the present study, serum sodium (Na) 
level non-significant (p>0.05) change in ESRD patients 
as compared with control group. The similar result has 
been reported by [43,26]. However, these results 
disagree with a previous study done by Williams, who 
related that to a major inability of the kidney to respond 
normally to change in Na concentration [62]. Probably 
the explained the normal level of serum Na due to 
reducing Na intake and humoral natriuretic factor in 
CRF that helps to increase sodium excretion and 
maintain normal Na balance. In addition, do not forget 
the effect of permanent hemodialysis on maintenance of 
normal Na concentration [63]. On the other hand, salt 
wasting is a common problem in advanced renal failure 
because of impaired tubular reabsorption of sodium 
[19], which may support our results. Also from data in 
the same table, found level of chloride (Cl) non-
significant (p> 0.05) difference with slightly higher in 
patients and this result conflict with study done by [64]. 
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Table 3. Minerals levels tests in HD patients and healthy individuals. 
 
Parameters Groups P-value Control Patients 
Ca mg/dl 7.70 ± 0.04 7.77 ± 0.10 0.894 NS 
P mg/dl 3.08 ± 0.03 8.07 ± 1.08 0.0241 * 
K meq/l 3.86 ± 0.03 5.32 ± 0.06 0.0238 * 
Na meq/l 139.80 ± 0.30 139.27 ± 0.61 0.873 NS 
Cl meq/l 100.00 ± 0.29 105.94 ± 0.62 0.779 NS 
 Mean ± SE 
 NS: Non-Significant. 
 ** Significant difference at (p< 0.01). 
 Significant difference at (p< 0.05). 
 
3.4 Evaluate the changes in serum Leptin and CRP 
concentrations 
The results showed in the Table (4) serum leptin 
level is highly significant (p< 0.01) increase in CRF 
patients as compared to control group, which is similar 
to the findings of the previous studies [43,65,23] but 
different with [66]. The difference could be due to 
discrepancies in numbers of patients in these studies. 
Hyperleptinemia observed might be the result of 
decreased renal clearance and consequent leptin 
retention in HD patients [67]. It is cleared from the 
circulation by the process of glomerular filtration 
followed by metabolic degradation in renal tubules 
[68]. The findings of the present study demonstrated 
that the patients with elevated CRP levels had markedly 
increased leptin concentration compared to control 
subjects. No mechanism has been proven to explain the 
relationship between CRP and leptin [69]. However, 
other factors such as hyperinsulinemia [70] and 
inflammation [71] have been implicated in augmenting 
leptin secretion in renal failure. The mean levels of 
CRP in this study were significantly and markedly 
higher in patients with CKD compared with that in 
controls, and this is due to the presence of infections 
among chronic kidney disease patients, as it is a strong 
predictor of mortality due to heart and blood vessels 
diseases among hemodialysis patients [72]. This finding 
is in close agreement with those reported by [43,22,28]. 
 
Table 4. Leptin and CRP tests in HD patients and healthy individuals. 
 
Parameters Groups P-value Control Patients 
Leptin ng/mL 11.58 ± 1.07 24.50 ± 1.76 0.0001 ** 
CRP mg/L 1.13 ± 0.28 41.11 ± 1.70 0.0001 ** 
 Mean ± SE 
 NS: Non-Significant. 
 ** Significant difference at (p< 0.01). 
 Significant difference at (p< 0.05). 
 
3.5 Evaluate the changes in Hematological 
parameters tests 
The results in the Table (5) shows a significant 
decrease (p< 0.05) in RBCs, Hb and platelet count in all 
patients group compared with control group. This 
finding is in accordance with previous studies that have 
been done by [73,74]. In addition, Han and Kishimoto 
concluded that the RBCs count, Hb, and PCV level in 
ESRD patients were significantly lower before HD 
when compared to healthy subjects [75]. The decrease 
in RBCs count in CRF patients may be due to the fact 
that patients with impaired kidney function have 
diminished erythropoietin (EPO) production in bone 
marrow, which leads to anemia [76,77]. In addition, 
CRF patients also show low erythrocyte half-life 
resulting from a small degree of hemolysis [78]. Such 
dysfunction can be partially corrected by 
supplementation with exogenous erythropoietin [79]. 
Also, erythropoietin potentiates the effect of 
megakaryocyte colony stimulating factors, 
acetylhydrolase (PAF-AH) and paraoxonase (PON1). In 
chronic renal disease, impaired erythropoietin secretion 
leads to a decrease in platelet count [80,81]. Moreover, 
showed that PCV and lymphocyte count was highly 
significant decrease (p<0.01) in HD patients as 
compared to the control group. In another study by 
Wasti et al., reported similar observations though [82]. 
While our results in contrast to the finding of the study 
done by [83], where a majority of the patients had a 
normal lymphocyte count. The decreased in 
lymphocytes count may be due to chronic infections, 
severe stress, kidney failure, or prolonged use of 
Cortisone injections [82]. 
 
Table 5. Hematological parameters tests in HD patients and healthy 
individuals. 
 
Parameters Groups P-value 
Control Patients 
Hb 14.10 ± 0.21 9.01 ± 0.11 0.0361 * 
PCV 43.38 ± 1.03 27.37 ± 0.33 0.0001 ** 
Lymphocyte 31.92 ± 0.76 22.66 ± 0.55 0.0026 ** 
RBC 4.86 ± 0.12 3.30 ± 0.04 0.0443 * 
PLT 215.20 ± 7.41 176.65 ± 4.52 0.02117 * 
 Mean ± SE 
 NS: Non-Significant. 
 ** Significant difference at (p< 0.01). 
 Significant difference at (p< 0.05). 
 
3. Conclusion 
 
From the findings of the present study, it shows 
highly significant increased serum concentration of 
leptin may be due to decreased renal clearance as well 
as elevated serum values of CRP indicates presence of 
systemic microinflammation in HD patients. Whereas a 
highly significant decrease in GFR and CrCl result from 
loss of the ability of the kidney to clearance. Also, 
abnormal mineral parameters and hematological 
parameters may be due to that patient with renal failure 
have no committed to restriction diet and reduced 
erythropoietin (EPO) production in bone marrow 
respectively. According to the results of this study, 
serum total protein and cholesterol cannot be used as 
diagnostic marker of nutrition disorders in patients on 
regular hemodialysis requires further investigation and 
clarification.  
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